Table 17. Recommendations of salvage treatment for triple negative breast cancer.
| Stratification | Level I recommendations | Level II recommendations | Level III recommendations |
|---|---|---|---|
| Taxanes-sensitive | (I) Taxane monotherapy | (I) Monotherapy | (I) Olaparib# (2A) |
| • Albumin paclitaxel (1A) | • Capecitabine (2A) | (II) Liposomal paclitaxel (2A) | |
| • Docetaxel (2A) | • Vinorelbine (2A) | (III) Liposomal doxorubicin (2B) | |
| • Paclitaxel (2A) | • Gemcitabine (2A) | (IV) Chemotherapy + PD-1 inhibitors (2B) | |
| (II) Combination therapy | • Etoposide (2B) | ||
| • TX (1A) | (II) Combination therapy | ||
| • GT (1A) | • Albumin paclitaxel + PD-1 inhibitor (2A) | ||
| • TP (2A) | • Taxanes + bevacizumab (2B) | ||
| Taxanes failure | (I) Monotherapy | (I) Monotherapy | (I) Olaparib# (2A) |
| • Eribulin (1A) | • Albumin paclitaxel* (2A) | (II) Liposomal doxorubicin (2B) | |
| • Vinorelbine (2A) | • Sacituzumab govitecan (2A) | (III) Liposomal paclitaxel (2B) | |
| • Gemcitabine (2A) | • Etoposide (2B) | (IV) Chemotherapy + PD-1 inhibitors (2B) | |
| • Capecitabine (2A) | (II) Combination therapy | ||
| (II) Combination therapy | • Capecitabine + bevacizumab (2B) | ||
| • NP (1A) | • Albumin paclitaxel + other chemotherapy drugs (2B) | ||
| • GP (1A) | |||
| • NX (2A) | |||
| • Utidelone + capecitabine (2A) |
*, consider switching to albumin paclitaxel if docetaxel or paclitaxel fails; #, recommended in the presence of BRCA1/2 mutations. T, taxene; G, gemcitabine; N, vinorelbine; X, capecitabine; P, platinum.